Abstract

BackgroundThe Ki67 Index has been extensively studied as a prognostic biomarker in breast cancer. However, its clinical adoption is largely hampered by the lack of a standardized method to assess Ki67 that limits inter-laboratory reproducibility. It is important to standardize the computation of the Ki67 Index before it can be effectively used in clincial practice.MethodIn this study, we develop a systematic approach towards standardization of the Ki67 Index. We first create the ground truth consisting of tumor positive and tumor negative nuclei by registering adjacent breast tissue sections stained with Ki67 and H&E. The registration is followed by segmentation of positive and negative nuclei within tumor regions from Ki67 images. The true Ki67 Index is then approximated with a linear model of the area of positive to the total area of tumor nuclei.ResultsWhen tested on 75 images of Ki67 stained breast cancer biopsies, the proposed method resulted in an average root mean square error of 3.34. In comparison, an expert pathologist resulted in an average root mean square error of 9.98 and an existing automated approach produced an average root mean square error of 5.64.ConclusionsWe show that it is possible to approximate the true Ki67 Index accurately without detecting individual nuclei and also statically demonstrate the weaknesses of commonly adopted approaches that use both tumor and non-tumor regions together while compensating for the latter with higher order approximations.

Highlights

  • The Ki67 Index has been extensively studied as a prognostic biomarker in breast cancer

  • According to the Breast Cancer Working Group, cell proliferation needs to be reported as a Ki67 Index that is defined as the percentage of positively stained cells within the total number of malignant cells scored [10]

  • True Ki67 vs. the proposed method The true Ki67 Index of 75 regions of interest (ROI) was computed from the manual annotations of Ki67 positive and negative nuclei

Read more

Summary

Introduction

The Ki67 Index has been extensively studied as a prognostic biomarker in breast cancer. The prognostic utility has been explored in numerous tumor types, most notably in the brain, neuroendocrine, Controversies exist regarding the prognostic and predictive role of Ki67 mainly due to lack of standardized methods to quantify Ki67 expression [9] and preanalytical methods used during the tissues fixation and slide preparation period. According to the Breast Cancer Working Group, cell proliferation needs to be reported as a Ki67 Index that is defined as the percentage of positively stained cells within the total number of malignant cells scored [10]. Pathologists often rely on estimating (i.e. eyeballing without formally counting) to approximate the Ki67 Index.

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call